Management of patients with HCV infection poorly tolerant to recombinant interferon alpha.
Hepatogastroenterology
; 47(31): 199-203, 2000.
Article
em En
| MEDLINE
| ID: mdl-10690609
ABSTRACT
BACKGROUND/AIMS:
To evaluate leukocyte interferon-alpha tolerability and efficacy in the retreatment of patients poorly tolerant to recombinant interferon-alpha.METHODOLOGY:
Patients with chronic hepatitis C, poorly tolerant to a previous interferon-alpha treatment (118 patients; 73 "relapsers" Group I; 45 "non-responders" Group II) were retreated with 6 MU tiw of leukocyte interferon-alpha for 6 months and then followed-up for 12-34 months. Only patients with complete regression of any previous interferon-related adverse event were included.RESULTS:
Three patients dropped out due to recurrence of a severe depressive syndrome. In 86/115 patients (75%) no significant lifestyle changes versus baseline were observed during retreatment, while 29 subjects experienced a moderately negative interference on their living habits. The different influence on the patients' quality of life of leukocyte interferon in comparison with the previous treatment was significant (P < 0.001). In 98 patients the interferon-related adverse events significantly decreased. After 12 months of follow-up, a sustained biochemical response was observed in 40 patients (Group I31; Group II9), and a persistent virological response in 28 (Group I23; Group II5).CONCLUSIONS:
The good compliance with leukocyte interferon administration shown by poorly tolerant patients, non-responders/relapsers to recombinant interferon, permitted a retreatment with full doses, so increasing the chance to obtain a larger number of sustained responses.
Buscar no Google
Bases de dados:
MEDLINE
Assunto principal:
Antivirais
/
Interferon Tipo I
/
Interferon-alfa
/
Hepatite C Crônica
Tipo de estudo:
Observational_studies
/
Prognostic_studies
Limite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Hepatogastroenterology
Ano de publicação:
2000
Tipo de documento:
Article
País de afiliação:
Itália